Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody

Yuki Majima; David Kryza; Mitsuaki Sanada; Jacqueline Sidi‐Boumedine; Patrick Mehlen; Benjamin Gibert; Jean Yves Blay; Fumiyoshi Okano

doi:10.1007/s00432-025-06236-4

Abstract

1 min read

This study demonstrates that radiopharmaceuticals targeting CAPRIN-1, including radiolabeled TRK-950 and TRK-950-F(ab')<sub>2</sub>, have high potential as radiopharmaceuticals.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2025

Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Philippe A. Cassier, Mitesh J. Borad, Sunil Sharma, Bertrand Dubois, Christophe Caux, Fumiyoshi Okano, Daniel D. Von Hoff, Jean Yves Blay

Preprint2025

Figure 1 from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Philippe A. Cassier, Mitesh J. Borad, Sunil Sharma, Bertrand Dubois, Christophe Caux, Fumiyoshi Okano, Daniel D. Von Hoff, Jean Yves Blay

Preprint2025

Data from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Philippe A. Cassier, Mitesh J. Borad, Sunil Sharma, Bertrand Dubois, Christophe Caux, Fumiyoshi Okano, Daniel D. Von Hoff, Jean Yves Blay

Article2023

A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer.

Philippe A. Cassier, Marc Matrana, Diana L. Hanna, Ben George, Sunil Sharma, Ronan J. Kelly, Fumiyoshi Okano, Daniel D. Von Hoff, Jean Yves Blay

Preprint2025

Table 4 from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Philippe A. Cassier, Mitesh J. Borad, Sunil Sharma, Bertrand Dubois, Christophe Caux, Fumiyoshi Okano, Daniel D. Von Hoff, Jean Yves Blay